• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,375.13
  • 0.92 %
  • $349.03
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Pliant Therapeutics, Inc. (PLRX) Stock Price, News & Analysis

Pliant Therapeutics, Inc. (PLRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$12.85

$0.12

(0.94%)

Day's range
$12.52
Day's range
$13.26
50-day range
$10.22
Day's range
$16.1
  • Country: US
  • ISIN: US7291391057
52 wk range
$10.22
Day's range
$19.62
  • CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.18
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (PLRX)
  • Company Pliant Therapeutics, Inc.
  • Price $12.85
  • Changes Percentage (0.94%)
  • Change $0.12
  • Day Low $12.52
  • Day High $13.26
  • Year High $19.62

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $40.00
  • High Stock Price Target $48.00
  • Low Stock Price Target $32.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.86
  • Trailing P/E Ratio -3.9
  • Forward P/E Ratio -3.9
  • P/E Growth -3.9
  • Net Income $-161,336,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Pliant Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of PLRX in the last quarter?

    In the last quarter Pliant Therapeutics, Inc. earnings were on Thursday, November, 7th. The Pliant Therapeutics, Inc. maker reported -$0.95 EPS for the quarter, beating analysts' consensus estimates of -$0.97 by $0.02.

  • What is the Pliant Therapeutics, Inc. stock price today?

    Today's price of Pliant Therapeutics, Inc. is $12.85 — it has increased by +0.94% in the past 24 hours. Watch Pliant Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Pliant Therapeutics, Inc. release reports?

    Yes, you can track Pliant Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Pliant Therapeutics, Inc. stock forecast?

    Watch the Pliant Therapeutics, Inc. chart and read a more detailed Pliant Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Pliant Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Pliant Therapeutics, Inc. stock ticker.

  • How to buy Pliant Therapeutics, Inc. stocks?

    Like other stocks, PLRX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Pliant Therapeutics, Inc.'s EBITDA?

    Pliant Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Pliant Therapeutics, Inc.’s financial statements.

  • What is the Pliant Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -102.1113924051, which equates to approximately -10,211.14%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Pliant Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Pliant Therapeutics, Inc.'s financials relevant news, and technical analysis. Pliant Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Pliant Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Pliant Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.